Trials / Completed
CompletedNCT00150020
Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance
Safety and Tolerability of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients With GI Intolerance
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 728 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric-coated mycophenolate sodium (EC-MPS) |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-02-01
- First posted
- 2005-09-08
- Last updated
- 2008-01-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00150020. Inclusion in this directory is not an endorsement.